TSO3 Inc.

Equities

TOS

CA8730151013

Delayed Toronto S.E. Other stock markets			5-day change	1st Jan Change
- ^CAD	-.--%		+0.59%	+12.50%

2019	9402-4874 Québec Inc. completed the acquisition of TSO3 Inc..	CI
2019	Tso3 Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	CI

TSO3 Inc. Appoints Linda Rosenstock as Chairperson

May 11, 2018 at 02:03 am

TSO3 Inc. announced that the board appointed Dr. Linda Rosenstock as Chairperson of the Board of Directors. Dr. Rosenstock is a physician executive in academia and government, with broad experience in clinical care, health care delivery, population health, research and health and regulatory policy.

Latest news about TSO3 Inc.

9402-4874 Québec Inc. completed the acquisition of TSO3 Inc..	30/09/19	CI
Tso3 Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	12/08/19	CI
9402-4874 Québec Inc. entered into a definitive arrangement agreement to acquire TSO3 Inc. for CAD 40.6 million.	11/08/19	CI
TSO3 Inc. Announces Group Purchasing Agreement with Capstone Health Alliance	11/06/19	CI
Transcript : TSO3 Inc., Q1 2019 Earnings Call, May 07, 2019	07/05/19
Tso3 Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	07/05/19	CI
TSO3 Inc. Announces Board Changes	02/04/19	CI
Transcript : TSO3 Inc., Q4 2018 Earnings Call, Mar 28, 2019	28/03/19
Tso3 Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2018	28/03/19	CI
TSO3 Inc. Reports Write Down of Tangible and Intangible Assets for the Fourth Quarter Ended December 31, 2018	26/03/19	CI
TSO3 Inc. Auditor Raises 'Going Concern' Doubt	26/03/19	CI
TSO3 Expands Duodenoscope Sterilization Testing	14/03/19	CI
TSO3 Inc. Announces the Results of the Company’S Clinical In-Use and Simulated Use Testing of the Terminal Sterilization of Duodenoscopes	30/01/19	CI
TSO3 Inc. Announces the Results of the Clinical In-Use and Simulated Use Testing of the Terminal Sterilization of Duodenoscopes	15/11/18	CI
Transcript : TSO3 Inc., Q3 2018 Earnings Call, Nov 07, 2018	07/11/18
TSO3 Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018	06/11/18	CI
TSO3 Inc. Wins Contract	30/10/18	CI
TSO3 Inc.(TSX:TOS) dropped from S&P Global BMI Index	24/09/18	CI
TSO3 Inc. Appoints Martin J. Madden to the Board of Directors	29/08/18	CI
TSO3 Inc. Joins with Uchealth in Announcing the First Patient Procedure in Colorado Performed with Duodenoscope Sterilized Using the STERIZONE® Technology	20/08/18	CI
Transcript : TSO3 Inc., Q2 2018 Earnings Call, Aug 08, 2018	08/08/18
TSP3 Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2018	07/08/18	CI
TSO3 Inc. Announces Closing of USD 20 Million Financing with Courage Capital	06/08/18	CI
Getinge and TSO3 Ends Exclusive Distribution Agreement on Low Temperature Sterilization	01/08/18	CI
TSO3 Inc. announced that it has received $20 million in funding	31/07/18	CI

Chart TSO3 Inc.

Duration

Period

More charts

Company Profile

TSO3 Inc is a Canada-based company engaged in the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment. The Company's products are used in the sterilization departments of hospital and other medical facilities. It also provides services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes. It has developed a sterilizer using a sterilization process based on ozone as the sterilizing agent. The Company's STERIZONE VP4 Sterilizer is a dual sterilant, low temperature sterilization system that utilizes vaporized hydrogen peroxide (H2O2) and ozone (O3) as its sterilants. The STERIZONE VP4 terminally sterilizes multiple channels in a single device.

Sector

More about the company